Vaca-Cartagena Bryan F, Mesa-Chavez Fernanda, Guajardo Ana S Ferrigno, Azim Hatem A, Rotolo Federico, Platas Alejandra, Fonseca Alan, Cruz-Ramos Marlid, Rodriguez Ana, Mohar Alejandro, Villarreal-Garza Cynthia
Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Mexico.
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL, USA.
Ther Adv Med Oncol. 2025 May 16;17:17588359251337493. doi: 10.1177/17588359251337493. eCollection 2025.
Young women with breast cancer (YWBC) typically undergo intensive treatment that negatively impacts their quality of life (QoL). However, limited information is available on how their QoL changes, as most research has focused on older patients.
To assess changes in QoL among YWBC, identify the most affected QoL domains, and identify the factors associated with these changes.
Joven & Fuerte is a multicenter cohort of women aged ⩽40 in Mexico with newly diagnosed BC from 2014 to 2020.
Participants completed the European Organization for Research and Treatment of Cancer Breast Cancer module QLQ-BR23 questionnaire at five different time points from enrollment until year 5 postdiagnosis. Clinical and treatment data were also collected. Group-based multivariate trajectory modeling was used to analyze longitudinal changes across QoL domains and classify patients into appropriate groups. Logistic models were then employed to identify associations between variables and group classification.
A total of 477 women (median age: 36 years; interquartile range 32-38) were included. Most had public health insurance (87%) and were diagnosed with stage II (49%) or III (39%) BC. Two trajectory groups, namely, "good" and "poor," were identified based on QLQ-BR23 scores. Most patients ( = 294, 62%) were in the poor group. In the good group, sexual enjoyment scores remained stable from baseline to year 5 (51.4), whereas those in the poor group decreased (51.0-37.3). Distress related to hair loss over time declined, with scores decreasing from 36.3 to 27.0 in the good trajectory group and from 43.4 to 31.2 in the poor trajectory group. For future perspective, the good group improved from 56.4 to 79.0, while the poor group increased from 39.3 to 57.2. Patients with human epidermal growth factor receptor 2-positive BC (adjusted odds ratio (aOR) = 0.57, 95% confidence interval (CI) 0.35-0.94, = 0.028) and those with public health insurance (aOR = 0.41, 95% CI 0.16-0.90, = 0.035) were less likely to belong to the poor trajectory group.
A high proportion of YWBC experience a poor QoL trajectory over time, particularly in areas related to sexual health, future perspective, and hair loss.
患有乳腺癌的年轻女性(YWBC)通常会接受强化治疗,这对她们的生活质量(QoL)产生负面影响。然而,关于她们的生活质量如何变化的信息有限,因为大多数研究都集中在老年患者身上。
评估YWBC的生活质量变化,确定受影响最大的生活质量领域,并确定与这些变化相关的因素。
Joven & Fuerte是墨西哥一个多中心队列研究,研究对象为2014年至2020年新诊断为乳腺癌的40岁及以下女性。
参与者在从入组到诊断后5年的五个不同时间点完成了欧洲癌症研究与治疗组织乳腺癌模块QLQ-BR23问卷。还收集了临床和治疗数据。基于组的多变量轨迹模型用于分析生活质量领域的纵向变化,并将患者分类到适当的组中。然后使用逻辑模型确定变量与组分类之间的关联。
共纳入477名女性(中位年龄:36岁;四分位间距32 - 38岁)。大多数人有公共医疗保险(87%),被诊断为II期(49%)或III期(39%)乳腺癌。根据QLQ-BR23评分确定了两个轨迹组,即“良好”组和“较差”组。大多数患者(n = 294,62%)属于较差组。在良好组中,从基线到第5年性愉悦得分保持稳定(51.4),而较差组的得分下降(51.0 - 37.3)。随着时间的推移,与脱发相关的困扰有所下降,良好轨迹组的得分从36.3降至27.0,较差轨迹组的得分从43.4降至31.2。对于未来展望,良好组从56.4提高到79.0,而较差组从39.3提高到57.2。人表皮生长因子受体2阳性乳腺癌患者(调整优势比(aOR)= 0.57,95%置信区间(CI)0.35 - 0.94,P = 0.028)和有公共医疗保险的患者(aOR = 0.41,95% CI 0.16 - 0.90,P = 0.035)属于较差轨迹组的可能性较小。
随着时间的推移,很大一部分YWBC经历了较差的生活质量轨迹,特别是在与性健康、未来展望和脱发相关的领域。